Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

-6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy - -6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy -

GlobeNewsWire • Dec 8, 2025

Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Coherus Oncology, Inc. ( CHRS ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Dennis Lanfear - Chairman, President & CEO Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division Excellent. Great. Well, thank you, everyone, for joining us, joining our fireside chat with Coherus.

Seeking Alpha • Nov 10, 2025

Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript

Coherus Oncology, Inc. ( CHRS ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dennis Lanfear - Chairman, President & CEO Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board Rosh Dias Sameer Goregaoker Bryan McMichael - Chief Financial Officer Rosh Dias - Chief Medical Officer Conference Call Participants Michael Nedelcovych - TD Cowen, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Jason Mccarthy - Maxim Group LLC, Research Division Nick Quartapella - Robert W. Baird & Co. Incorporated, Research Division Douglas Tsao - H.C.

Seeking Alpha • Nov 7, 2025

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients –

GlobeNewsWire • Nov 7, 2025

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025 – – Conference call today at 5:00 p.m. Eastern Standard Time – REDWOOD CITY, Calif.

GlobeNewsWire • Nov 6, 2025

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus Oncology (CHRS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.01 per share a year ago.

Zacks Investment Research • Nov 7, 2025

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

–  Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer.

GlobeNewsWire • Nov 6, 2025

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

GlobeNewsWire • Oct 30, 2025

Coherus Oncology to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its presentations at the following upcoming conferences:

GlobeNewsWire • Oct 23, 2025

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

Among the recent momentum standouts in the biotechnology sector, four stocks have drawn considerable investor attention, entering the top 10th percentile of momentum-ranked stocks based on decisive week-on-week percentile gains.

Benzinga • Oct 10, 2025